WO2002083651A3 - Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques - Google Patents
Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques Download PDFInfo
- Publication number
- WO2002083651A3 WO2002083651A3 PCT/CA2002/000512 CA0200512W WO02083651A3 WO 2002083651 A3 WO2002083651 A3 WO 2002083651A3 CA 0200512 W CA0200512 W CA 0200512W WO 02083651 A3 WO02083651 A3 WO 02083651A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ictogenic
- compounds
- pyrimidine compounds
- methods
- epileptogenic agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002444148A CA2444148A1 (fr) | 2001-04-11 | 2002-04-11 | Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques |
JP2002581407A JP2004527535A (ja) | 2001-04-11 | 2002-04-11 | 抗発作発生剤および/または抗癲癇誘発剤としてのピリミジン化合物 |
EP02717913A EP1385831A2 (fr) | 2001-04-11 | 2002-04-11 | Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28298701P | 2001-04-11 | 2001-04-11 | |
US60/282,987 | 2001-04-11 | ||
US28594001P | 2001-04-23 | 2001-04-23 | |
US60/285,940 | 2001-04-23 | ||
US31074801P | 2001-08-07 | 2001-08-07 | |
US60/310,748 | 2001-08-07 | ||
US9993402A | 2002-03-13 | 2002-03-13 | |
US10/099,934 | 2002-03-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002083651A2 WO2002083651A2 (fr) | 2002-10-24 |
WO2002083651A3 true WO2002083651A3 (fr) | 2002-12-19 |
Family
ID=27493095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2002/000512 WO2002083651A2 (fr) | 2001-04-11 | 2002-04-11 | Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1385831A2 (fr) |
JP (1) | JP2004527535A (fr) |
CA (1) | CA2444148A1 (fr) |
WO (1) | WO2002083651A2 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004009559A2 (fr) * | 2002-07-18 | 2004-01-29 | Queen's University At Kingston | Composes de dihydro-uracile utilises comme agents anti-ictogenes ou anti-epileptogenes |
CA2523739A1 (fr) * | 2003-04-25 | 2004-11-11 | University College Cardiff Consultants Limited | Composes heterocycliques destines a etre utilises dans le traitement d'infections virales |
BRPI0508310A (pt) * | 2004-03-02 | 2007-07-24 | Hoffmann La Roche | derivados de 4-(sulfanil-pirimidin-4-ilmetil)-morfolina e compostos relacionados como ligandos do receptor gaba, para o tratamento de ansiedade, depressão e epilepsia |
AU2009209811B2 (en) * | 2008-01-30 | 2011-07-21 | Shin Poong Pharmaceutical Co., Ltd. | Novel quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same |
DE102008030091B4 (de) * | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracilderivate und deren Verwendung |
US9809571B2 (en) | 2013-01-07 | 2017-11-07 | University Of Southern California | Deoxyuridine triphosphatase inhibitors |
WO2015103489A1 (fr) * | 2014-01-03 | 2015-07-09 | University Of Southern California | Hétéroatome contenant des inhibiteurs de la désoxyuridine triphosphatase |
CN103788095A (zh) * | 2014-01-20 | 2014-05-14 | 四川大学华西医院 | 2,4(1h,3h)-嘧啶二酮衍生物及其制备方法 |
CN104788389A (zh) * | 2015-04-09 | 2015-07-22 | 新乡市创新生物科技有限公司 | 一种5-溴尿嘧啶的制备方法 |
JP6836589B2 (ja) | 2015-07-08 | 2021-03-03 | シーブイ6 セラピューティクス (エヌアイ) リミテッド | ヒダントインを含むデオキシウリジントリホスファターゼ阻害剤 |
WO2017006271A1 (fr) | 2015-07-08 | 2017-01-12 | University Of Southern California | Inhibiteurs de désoxyuridine triphosphatase contenant une liaison sulfonyle aminée |
WO2017006270A1 (fr) | 2015-07-08 | 2017-01-12 | University Of Southern California | Inhibiteurs de la désoxyuridine triphosphatase |
WO2017006283A1 (fr) | 2015-07-08 | 2017-01-12 | Cv6 Therapeutics (Ni) Limited | Inhibiteurs de désoxyuridine triphosphatase contenant une liaison cyclopropano |
WO2017123823A1 (fr) * | 2016-01-12 | 2017-07-20 | Bioelectron Technology Corporation | Inhibiteurs de sulfure:quinone oxydoréductase alkyle, acyle, urée, et aza-uracile |
US11174271B2 (en) | 2016-11-23 | 2021-11-16 | Cv6 Therapeutics (Ni) Limited | 6-membered uracil isosteres |
WO2018098208A1 (fr) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Inhibiteurs de désoxyuridine triphosphatase liés à un cycle azote |
US10858344B2 (en) | 2016-11-23 | 2020-12-08 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
US11014924B2 (en) | 2016-11-23 | 2021-05-25 | Cv6 Therapeutics (Ni) Limited | Hydantoin containing deoxyuridine triphosphatase inhibitors |
WO2018098209A1 (fr) | 2016-11-23 | 2018-05-31 | Cv6 Therapeutics (Ni) Limited | Composés aminosulfonyle |
WO2018128720A1 (fr) | 2017-01-05 | 2018-07-12 | Cv6 Therapeutics (Ni) Limited | Composés contenant de l'uracile |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252576A (en) * | 1988-07-18 | 1993-10-12 | Yamasa Shoyu Kabushiki Kaisha | 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient |
DE4300912A1 (de) * | 1993-01-15 | 1994-07-21 | Merck Patent Gmbh | Chinazolinderivate |
WO1995019346A1 (fr) * | 1994-01-14 | 1995-07-20 | Sandoz Ltd. | Quinazoline-2,4-diones |
WO2000011952A1 (fr) * | 1998-08-31 | 2000-03-09 | Pro-Neuron, Inc. | Compositions et procedes de traitement des maladies mitochondriales |
WO2000050043A1 (fr) * | 1999-02-23 | 2000-08-31 | The Regents Of The University Of California | Procedes de traitement de troubles mitochondriaux |
WO2001051490A1 (fr) * | 2000-01-14 | 2001-07-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Analogues nucleosidiques de methanocarba cycloalkyle |
-
2002
- 2002-04-11 WO PCT/CA2002/000512 patent/WO2002083651A2/fr active Application Filing
- 2002-04-11 EP EP02717913A patent/EP1385831A2/fr not_active Withdrawn
- 2002-04-11 CA CA002444148A patent/CA2444148A1/fr not_active Abandoned
- 2002-04-11 JP JP2002581407A patent/JP2004527535A/ja not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5252576A (en) * | 1988-07-18 | 1993-10-12 | Yamasa Shoyu Kabushiki Kaisha | 1-amino-5-halogenouracils, process for their preparation, and central nervous system depressants containing same as active ingredient |
DE4300912A1 (de) * | 1993-01-15 | 1994-07-21 | Merck Patent Gmbh | Chinazolinderivate |
WO1995019346A1 (fr) * | 1994-01-14 | 1995-07-20 | Sandoz Ltd. | Quinazoline-2,4-diones |
WO2000011952A1 (fr) * | 1998-08-31 | 2000-03-09 | Pro-Neuron, Inc. | Compositions et procedes de traitement des maladies mitochondriales |
WO2000050043A1 (fr) * | 1999-02-23 | 2000-08-31 | The Regents Of The University Of California | Procedes de traitement de troubles mitochondriaux |
WO2001051490A1 (fr) * | 2000-01-14 | 2001-07-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Analogues nucleosidiques de methanocarba cycloalkyle |
Non-Patent Citations (1)
Title |
---|
CONNOLLY G P ET AL: "Uridine and its nucleotides: biological actions, therapeutic potentials", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 20, no. 5, 1 May 1999 (1999-05-01), pages 218 - 225, XP004170246, ISSN: 0165-6147 * |
Also Published As
Publication number | Publication date |
---|---|
JP2004527535A (ja) | 2004-09-09 |
CA2444148A1 (fr) | 2002-10-24 |
EP1385831A2 (fr) | 2004-02-04 |
WO2002083651A2 (fr) | 2002-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004009559A3 (fr) | Composes de dihydro-uracile utilises comme agents anti-ictogenes ou anti-epileptogenes | |
WO2002083651A3 (fr) | Composes de pyrimidine en tant qu'agents anti-ictogeniques et/ou anti-epileptiques | |
WO1998040055A3 (fr) | Agents anti-epileptogenes | |
AU2002352832A1 (en) | 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them | |
WO2002073208A3 (fr) | Agents antiepileptogenes | |
WO2004028454A3 (fr) | 1, 3, 5-triazines destinees au traitement de maladies virales | |
AP1869A (en) | b2- Adrenergic receptor agonists. | |
WO2001006989A3 (fr) | Procedes et compositions permettant d'inhiber l'accumulation des polypeptides associee aux troubles neurologiques | |
EP1478322A4 (fr) | Beta-2'-OU 3'-HALONUCLEOSIDES | |
WO1999054326A8 (fr) | Dihydropyrimidines | |
WO2003042214A3 (fr) | Antagonistes de recepteur d'adenosine a¿2b? | |
ZA979961B (en) | 5-HT1F agonists | |
NO20022655D0 (no) | <Beta>-2-adrenerge reseptoragonister | |
WO2002064594A3 (fr) | Pyrido-pyrimidines substituees en position 6 | |
WO2004084453A3 (fr) | Procedes de fabrication de 2'-desoxy-$g(b)-l-nucleosides | |
EP0835869A3 (fr) | Agonistes du Récepteur sérotonine 5-HT1F | |
WO2003057145A3 (fr) | 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones substitues, leurs derives et leurs utilisations | |
MXPA03009527A (es) | PROCEDIMIENTO PARA LA PREPARACIoN DE INDENOS 1,3-SUSTITUIDOS Y COMPUESTOS AZAPOLICICLICOS CONDENSADOS CON ARILO. | |
WO2001098279A3 (fr) | Bis-arylsulfones | |
WO2002053519A3 (fr) | Analogues de polyamine hydrophobe et procedes d'utilisation correspondants | |
HUP0303590A3 (en) | Method for the production of 4,6-diaminopyrimido[5,4-d]pyrimidines | |
AU2759800A (en) | Processes and intermediates for the preparation of 1,3-oxazin-6-ones and uracils | |
ZA200003768B (en) | Methods and compositions for treating diseases and conditions of the eye. | |
WO2000021513A3 (fr) | Procedes pour traiter la sclerose en plaques | |
WO2003051299A3 (fr) | Rifamycines au sulfhydryle et utilisations de ces dernieres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2444148 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002581407 Country of ref document: JP Ref document number: 528880 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002249037 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002717913 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002717913 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |